Mangoceuticals, Inc. (MGRX) stock
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$0.15−0.03 (-16.22%)
Close on Nov 13, 2026Market cap $3.34MP/E –Yield –
Mangoceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Mangoceuticals's profit margin for the twelve months ending Jun 30, 2026 was -4791.3%. For fiscal 2025 it was -4526.8%, against -1413.6% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4526.8% | −3113.1 |
| FY2024 | Dec 31, 2024 | -1413.6% | −154.2 |
| FY2023 | Dec 31, 2023 | -1259.4% | +21092.7 |
| FY2022 | Dec 31, 2022 | -22352.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1909.1% | +1312.5 |
| Q1 FY2026 | Mar 31, 2026 | -5014.7% | −587.3 |
| Q4 FY2025 | Dec 31, 2025 | -2935.1% | −1083.9 |
| Q3 FY2025 | Sep 30, 2025 | -9042.8% | −7543.8 |
| Q2 FY2025 | Jun 30, 2025 | -3221.6% | −1756.2 |
| Q1 FY2025 | Mar 31, 2025 | -4427.4% | −3321.5 |
| Q4 FY2024 | Dec 31, 2024 | -1851.2% | −800.4 |
| Q3 FY2024 | Sep 30, 2024 | -1499.0% | −765.0 |
| Q2 FY2024 | Jun 30, 2024 | -1465.4% | +151.8 |
| Q1 FY2024 | Mar 31, 2024 | -1105.9% | +1436.7 |
| Q4 FY2023 | Dec 31, 2023 | -1050.9% | – |
| Q3 FY2023 | Sep 30, 2023 | -734.0% | – |
| Q2 FY2023 | Jun 30, 2023 | -1617.2% | – |
| Q1 FY2023 | Mar 31, 2023 | -2542.5% | – |
See a number that looks wrong?